



**BlueCross  
BlueShield**

Federal Employee Program.

## **TRASTUZUMAB**

Herceptin (trastuzumab), Hercessi\* (trastuzumab-strf), Herzuma (trastuzumab-pkrb),  
**Kanjinti** (trastuzumab-anns), **Ogivri** (trastuzumab-dkst), **Ontruzant** (trastuzumab-dttb),  
Trazimera (trastuzumab-qyyp)

Preferred products: Kanjinti, Ogivri, Ontruzant

\*Product covered on the medical benefit only

## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 18 years of age or greater

### **Diagnoses**

Patient must have **ONE** of the following:

1. HER2-overexpressing breast cancer
  - a. HER2 protein overexpression or HER2 gene amplification as determined by an FDA-approved test
2. HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
  - a. HER2 protein overexpression or HER2 gene amplification as determined by an FDA-approved test
3. Unresectable or metastatic colorectal cancer
  - a. RAS wild-type, as determined by an FDA-approved test
  - b. HER2-positive
  - c. Cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
  - d. Used in combination with tucatinib

**AND ALL** of the following:

- a. Prescriber agrees to monitor for cardiac function and pulmonary toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with trastuzumab and for 7 months after the last dose
- c. **Non-preferred medications only**: Inadequate treatment response, intolerance, or contraindication to **ONE** of the preferred products (Kanjinti, Ogivri, Ontruzant)

## **Prior - Approval Limits**

**Duration** 12 months



**BlueCross  
BlueShield**

Federal Employee Program.

## **TRASTUZUMAB**

Herceptin (trastuzumab), Hercessi\* (trastuzumab-strf), Herzuma (trastuzumab-pkrb),  
**Kanjinti** (trastuzumab-anns), **Ogivri** (trastuzumab-dkst), **Ontruzant** (trastuzumab-dttb),  
Trazimera (trastuzumab-qyyp)

Preferred products: Kanjinti, Ogivri, Ontruzant

\*Product covered on the medical benefit only

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

### **Diagnoses**

Patient must have **ONE** of the following:

1. HER2-overexpressing breast cancer
2. HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
3. Unresectable or metastatic colorectal cancer
  - a. Used in combination with tucatinib

**AND ALL** of the following:

- a. Prescriber agrees to monitor for cardiac function and pulmonary toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Trastuzumab and for 7 months after the last dose

## **Prior – Approval *Renewal* Limits**

Same as above